| Literature DB >> 32119141 |
Eleanor Russell-Goldman1, Rosalynn M Nazarian2.
Abstract
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. This report is the first known case of DI-SCLE with positive anti-Ro antibodies in this setting. We also summarize the literature describing DI-SCLE in association with targeted therapies to date and its possible association with dysregulation of the vascular endothelial growth factor pathway.Entities:
Keywords: CDK4/6 inhibitor; anti-Ro; drug-induced; palbociclib; subacute cutaneous lupus erythematosus; targeted therapy
Mesh:
Substances:
Year: 2020 PMID: 32119141 DOI: 10.1111/cup.13673
Source DB: PubMed Journal: J Cutan Pathol ISSN: 0303-6987 Impact factor: 1.587